Pursuing a selective path
Cholangiocarcinoma and further research
For first-line treatment of cholangiocarcinoma
BridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations
BridgeBio Pharma’s QED Therapeutics Receives Fast Track Designation For Infigratinib In Adults With First-Line Advanced Or Metastatic Cholangiocarcinoma And Orphan Drug Designation For Infigratinib For Treatment Of Cholangiocarcinoma
QED and Parent Company BridgeBio Announce Preclinical Data Supporting Tolerability and Activity of Low-dose Infigratinib in Treating Achondroplasia
Receive updates on the development of infigratinib and breaking news from QED Therapeutics.
75 Federal Street
San Francisco, CA 94107
By selecting “Proceed” you will leave QEDTx.com and be directed to an external website.